Hydrogen sulfide: a new EDRF | Zendy

Rui Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hydrogen sulfide: a new EDRF

Author(s) -

Rui Wang

Publication year - 2009

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2009.221

Subject(s) - cystathionine beta synthase , endothelium derived relaxing factor , endothelium , cystathionine gamma lyase , nitric oxide , chemistry , nitric oxide synthase , microbiology and biotechnology , endothelium derived hyperpolarizing factor , cholinergic , biochemistry , endocrinology , medicine , biology , cysteine , enzyme , charybdotoxin , organic chemistry

The first endothelium-derived relaxing factor (EDRF) ever identified is a gasotransmitter, nitric oxide (NO). Recent studies have provided several lines of evidence to support the premise that hydrogen sulfide (H(2)S), another gasotransmitter, is a new EDRF. H(2)S production is catalyzed in mammalian cells by cystathionine beta-synthase (CBS) and/or cystathionine gamma-lyase (CSE). The expression of CSE proteins and the activity of CBS have been observed in vascular endothelial cells. A measurable amount of H(2)S is produced from endothelium upon muscarinic cholinergic stimulation. The endothelium-dependent vasorelaxation induced by H(2)S shares many common mechanistic traits with those of endothelium-derived hyperpolarizing factor (EDHF). Deficiency in CSE expression increases blood pressure in CSE knockout mice and significantly diminishes endothelium-dependent relaxation of resistance arteries. More extensive and mechanistic studies in the future will help to determine whether H(2)S is a new EDRF or the very EDHF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research